Completed PHASE2 INTERVENTIONAL NCT00211497

Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne

A Phase II, Randomized, Vehicle-Controlled, Double-Blind, Multi-Center Study to Evaluate Safety and Efficacy of MBI 226 1.25% and 2.5% Acne Solutions Applied Topically for 12 Weeks to Subjects With Acne Vulgaris

Sponsor: BioWest Therapeutics Inc

Conditions Acne Acne Vulgaris Propionibacterium Acnes

Interventions MBI 226 Acne Solutions

Updated 4 times since 2017 Last updated: Sep 13, 2005 Started: Jan 31, 2003 Completion: Sep 30, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Acne and Acne Vulgaris and is currently completed. BioWest Therapeutics Inc leads this study, which shows 4 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2017 — Jan 2021 [monthly]

Completed PHASE2

First recorded

Jan 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BioWest Therapeutics Inc

Data source: BioWest Therapeutics Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.